SAN DIEGO, January 5, 2018– - Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology and metabolic diseases, announced today that it will be presenting at Biotech Showcase ™ 2018, which will be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
Dr. Irene Wang, President and R&D Director will present at the Biotech Showcase™ as follows:
Date: Wednesday, January 10, 2018
Time: 11:15am (PST)
Room: Hilton/Franciscan D
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Lin BioScience’s lead candidates, which include a first-in-class oral therapy
for macular degeneration (LBS-008) and a natural cell cycle inhibitor for a variety of cancers (LBS-007), are initiating their fully-funded Phase I clinical trials this year. The Company’s most recent regulatory milestones was receiving Orphan Drug Status for LBS-008, which is also part of the NIH Blueprint Program.
“We believe our partnership with the NIH Blueprint Program and the Orphan Drug Status designation by the FDA confirms that our approach to developing drug candidates through our RBP4 and oncology platforms show considerable therapeutic promise,” commented Dr. Tom Lin, CEO of Lin Bioscience. “We’re excited to share the latest developments in our clinical program with potential partners and investors at Biotech Showcase ™ 2018.”
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Lin BioScience will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
About Lin BioScience, Inc.
Lin BioScience, Inc. is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Lin BioScience's diverse pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in ophthalmology, oncology and metabolic diseases.
For more information, please visit www.linbioscience.com.
Additional links and information:
Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
Follow Lin BioScience on Twitter: @LinBioScience
Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton - #BiotechShowcase